Search in:

Expert Opinion on Investigational Drugs Volume 23, 2014 - Issue 4

Submit an article Journal homepage

486

Views

CrossRef citations to date

Altmetric

Meeting Highlights

An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013

Miroslava ValentovaApplied Cachexia Research, Charité Medical School, Department of Cardiology, Campus Virchow-Klinikum, Augustenburger Platz 1, D - 13353 Berlin, Germany+49 30 450 553 577; +49 30 450 553 951; [email protected];Faculty Hospital, 1st Department of Internal Medicine, Bratislava, Slovak Republic

, MD &

Stephan von HaehlingApplied Cachexia Research, Charité Medical School, Department of Cardiology, Campus Virchow-Klinikum, Augustenburger Platz 1, D - 13353 Berlin, Germany+49 30 450 553 577; +49 30 450 553 951; [email protected]

, MD PhD

Pages 573-578 | Published online: 04 Feb 2014

Cite this article
https://doi.org/10.1517/13543784.2014.881799
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol 2011;301:R267-75
PubMed Web of Science ®Google Scholar
Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39
PubMed Web of Science ®Google Scholar
Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373:1429-39
PubMed Web of Science ®Google Scholar
Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196-206
PubMed Web of Science ®Google Scholar
Metra M, Ponikowski P, Cotter G, et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J 2013. [ Epub ahead of print]
Google Scholar
Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011;331:1439-43
PubMed Web of Science ®Google Scholar
Cleland JGF, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011;378:676-83
PubMed Web of Science ®Google Scholar
Gheorghiade M. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013;309:1125
PubMed Web of Science ®Google Scholar
Maggioni AP, Greene SJ, Fonarow GC, et al. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J 2013. [ Epub ahead of print]
Web of Science ®Google Scholar
Bart BA, Goldsmith SR, Lee KL, et al. Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the heart failure clinical research network. J Card Fail 2012;18:176-82
PubMed Web of Science ®Google Scholar
Boerrigter G, Costello-Boerrigter LC, Cataliotti A, et al. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 2007;49:1128-33
PubMed Web of Science ®Google Scholar
Erdmann E, Semigran MJ, Nieminen MS, et al. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J 2013;34:57-67
PubMed Web of Science ®Google Scholar
Gheorghiade M, Greene SJ, Filippatos G, et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 2012;14:1056-66
PubMed Web of Science ®Google Scholar
Venkatasubramanian S, Newby DE, Lang NN. Urocortins in heart failure. Biochem Pharmacol 2010;80:289-96
PubMed Web of Science ®Google Scholar
Gheorghiade M, Greene SJ, Ponikowski P, et al. Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. Eur J Heart Fail 2013;15:679-89
PubMed Web of Science ®Google Scholar
Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013;34:2281-329
PubMed Web of Science ®Google Scholar
Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013;369:1395-405
PubMed Web of Science ®Google Scholar
Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013;368:1210-19
PubMed Web of Science ®Google Scholar
Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16(Suppl 3):3-13
PubMed Web of Science ®Google Scholar
McMurray JJV, Anand IS, Diaz R, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity–mortality trial. Eur J Heart Fail 2009;11:795-801
PubMed Web of Science ®Google Scholar
Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013;15:808-17
PubMed Web of Science ®Google Scholar
Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173-84
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date